PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti鈥揚D-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
The global market for PD-L1 and PIK3CA Testing Product was estimated to be worth US$ 521.8 million in 2023 and is forecast to a readjusted size of US$ 1099.4 million by 2030 with a CAGR of 11.0% during the forecast period 2024-2030
The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.
PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.
North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.
麻豆原创 competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PD-L1 and PIK3CA Testing Product, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of PD-L1 and PIK3CA Testing Product by region & country, by Type, and by Application.
The PD-L1 and PIK3CA Testing Product market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 and PIK3CA Testing Product.
麻豆原创 Segmentation
By Company
Agilent Technologies
Roche
QIAGEN
EntroGen
Foundation Medicine
Amoy Diagnostics
ACCB Biotech
Segment by Type:
PD-L1
PIK3CA
Segment by Application
Hospital
Diagnostic Center
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PD-L1 and PIK3CA Testing Product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of PD-L1 and PIK3CA Testing Product in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of PD-L1 and PIK3CA Testing Product in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 PD-L1 and PIK3CA Testing Product Product Introduction
1.2 Global PD-L1 and PIK3CA Testing Product 麻豆原创 Size Forecast
1.2.1 Global PD-L1 and PIK3CA Testing Product Sales Value (2019-2030)
1.2.2 Global PD-L1 and PIK3CA Testing Product Sales Volume (2019-2030)
1.2.3 Global PD-L1 and PIK3CA Testing Product Sales Price (2019-2030)
1.3 PD-L1 and PIK3CA Testing Product 麻豆原创 Trends & Drivers
1.3.1 PD-L1 and PIK3CA Testing Product Industry Trends
1.3.2 PD-L1 and PIK3CA Testing Product 麻豆原创 Drivers & Opportunity
1.3.3 PD-L1 and PIK3CA Testing Product 麻豆原创 Challenges
1.3.4 PD-L1 and PIK3CA Testing Product 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global PD-L1 and PIK3CA Testing Product Players Revenue Ranking (2023)
2.2 Global PD-L1 and PIK3CA Testing Product Revenue by Company (2019-2024)
2.3 Global PD-L1 and PIK3CA Testing Product Players Sales Volume Ranking (2023)
2.4 Global PD-L1 and PIK3CA Testing Product Sales Volume by Company Players (2019-2024)
2.5 Global PD-L1 and PIK3CA Testing Product Average Price by Company (2019-2024)
2.6 Key Manufacturers PD-L1 and PIK3CA Testing Product Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers PD-L1 and PIK3CA Testing Product Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of PD-L1 and PIK3CA Testing Product
2.9 PD-L1 and PIK3CA Testing Product 麻豆原创 Competitive Analysis
2.9.1 PD-L1 and PIK3CA Testing Product 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by PD-L1 and PIK3CA Testing Product Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 and PIK3CA Testing Product as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 PD-L1
3.1.2 PIK3CA
3.2 Global PD-L1 and PIK3CA Testing Product Sales Value by Type
3.2.1 Global PD-L1 and PIK3CA Testing Product Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global PD-L1 and PIK3CA Testing Product Sales Value, by Type (2019-2030)
3.2.3 Global PD-L1 and PIK3CA Testing Product Sales Value, by Type (%) (2019-2030)
3.3 Global PD-L1 and PIK3CA Testing Product Sales Volume by Type
3.3.1 Global PD-L1 and PIK3CA Testing Product Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global PD-L1 and PIK3CA Testing Product Sales Volume, by Type (2019-2030)
3.3.3 Global PD-L1 and PIK3CA Testing Product Sales Volume, by Type (%) (2019-2030)
3.4 Global PD-L1 and PIK3CA Testing Product Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Diagnostic Center
4.1.3 Others
4.2 Global PD-L1 and PIK3CA Testing Product Sales Value by Application
4.2.1 Global PD-L1 and PIK3CA Testing Product Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global PD-L1 and PIK3CA Testing Product Sales Value, by Application (2019-2030)
4.2.3 Global PD-L1 and PIK3CA Testing Product Sales Value, by Application (%) (2019-2030)
4.3 Global PD-L1 and PIK3CA Testing Product Sales Volume by Application
4.3.1 Global PD-L1 and PIK3CA Testing Product Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global PD-L1 and PIK3CA Testing Product Sales Volume, by Application (2019-2030)
4.3.3 Global PD-L1 and PIK3CA Testing Product Sales Volume, by Application (%) (2019-2030)
4.4 Global PD-L1 and PIK3CA Testing Product Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global PD-L1 and PIK3CA Testing Product Sales Value by Region
5.1.1 Global PD-L1 and PIK3CA Testing Product Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global PD-L1 and PIK3CA Testing Product Sales Value by Region (2019-2024)
5.1.3 Global PD-L1 and PIK3CA Testing Product Sales Value by Region (2025-2030)
5.1.4 Global PD-L1 and PIK3CA Testing Product Sales Value by Region (%), (2019-2030)
5.2 Global PD-L1 and PIK3CA Testing Product Sales Volume by Region
5.2.1 Global PD-L1 and PIK3CA Testing Product Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global PD-L1 and PIK3CA Testing Product Sales Volume by Region (2019-2024)
5.2.3 Global PD-L1 and PIK3CA Testing Product Sales Volume by Region (2025-2030)
5.2.4 Global PD-L1 and PIK3CA Testing Product Sales Volume by Region (%), (2019-2030)
5.3 Global PD-L1 and PIK3CA Testing Product Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
5.4.2 North America PD-L1 and PIK3CA Testing Product Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
5.5.2 Europe PD-L1 and PIK3CA Testing Product Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
5.6.2 Asia Pacific PD-L1 and PIK3CA Testing Product Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
5.7.2 South America PD-L1 and PIK3CA Testing Product Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
5.8.2 Middle East & Africa PD-L1 and PIK3CA Testing Product Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions PD-L1 and PIK3CA Testing Product Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions PD-L1 and PIK3CA Testing Product Sales Value
6.2.1 Key Countries/Regions PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.2.2 Key Countries/Regions PD-L1 and PIK3CA Testing Product Sales Volume, 2019-2030
6.3 United States
6.3.1 United States PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.3.2 United States PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.3.3 United States PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.4.2 Europe PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.5.2 China PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.5.3 China PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.6.2 Japan PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.7.2 South Korea PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.8.2 Southeast Asia PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India PD-L1 and PIK3CA Testing Product Sales Value, 2019-2030
6.9.2 India PD-L1 and PIK3CA Testing Product Sales Value by Type (%), 2023 VS 2030
6.9.3 India PD-L1 and PIK3CA Testing Product Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Agilent Technologies
7.1.1 Agilent Technologies Company Information
7.1.2 Agilent Technologies Introduction and Business Overview
7.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Product Product Offerings
7.1.5 Agilent Technologies Recent Development
7.2 Roche
7.2.1 Roche Company Information
7.2.2 Roche Introduction and Business Overview
7.2.3 Roche PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Roche PD-L1 and PIK3CA Testing Product Product Offerings
7.2.5 Roche Recent Development
7.3 QIAGEN
7.3.1 QIAGEN Company Information
7.3.2 QIAGEN Introduction and Business Overview
7.3.3 QIAGEN PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.3.4 QIAGEN PD-L1 and PIK3CA Testing Product Product Offerings
7.3.5 QIAGEN Recent Development
7.4 EntroGen
7.4.1 EntroGen Company Information
7.4.2 EntroGen Introduction and Business Overview
7.4.3 EntroGen PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.4.4 EntroGen PD-L1 and PIK3CA Testing Product Product Offerings
7.4.5 EntroGen Recent Development
7.5 Foundation Medicine
7.5.1 Foundation Medicine Company Information
7.5.2 Foundation Medicine Introduction and Business Overview
7.5.3 Foundation Medicine PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Foundation Medicine PD-L1 and PIK3CA Testing Product Product Offerings
7.5.5 Foundation Medicine Recent Development
7.6 Amoy Diagnostics
7.6.1 Amoy Diagnostics Company Information
7.6.2 Amoy Diagnostics Introduction and Business Overview
7.6.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Product Offerings
7.6.5 Amoy Diagnostics Recent Development
7.7 ACCB Biotech
7.7.1 ACCB Biotech Company Information
7.7.2 ACCB Biotech Introduction and Business Overview
7.7.3 ACCB Biotech PD-L1 and PIK3CA Testing Product Sales, Revenue and Gross Margin (2019-2024)
7.7.4 ACCB Biotech PD-L1 and PIK3CA Testing Product Product Offerings
7.7.5 ACCB Biotech Recent Development
8 Industry Chain Analysis
8.1 PD-L1 and PIK3CA Testing Product Industrial Chain
8.2 PD-L1 and PIK3CA Testing Product Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 PD-L1 and PIK3CA Testing Product Sales Model
8.5.2 Sales Channel
8.5.3 PD-L1 and PIK3CA Testing Product Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Agilent Technologies
Roche
QIAGEN
EntroGen
Foundation Medicine
Amoy Diagnostics
ACCB Biotech
听
听
*If Applicable.